Clinical trials: Blood Pressure, Resistant
- Condition Blood Pressure, Resistant
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Resistant Hypertension
A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its Safety
The goal of this clinical trial is to show the blood pressure lowering effect of aprocitentan, a new drug, when added to other anti-hypertensive drugs of patients with difficult to control (resistant) high blood pressure…
- Trial name
- PRECISION (NCT03541174)
- Testing
- Aprocitentan 12.5 mg, Aprocitentan 25 mg
- Where
- 159 sites in United States, Australia and 18 more
- Volunteers
- 730 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Hypertension
Rheos® Pivotal Trial
The purpose of this clinical trial is to demonstrate the efficacy and safety of the Rheos system in subjects with hypertension that are resistant to treatment with at least three anti-hypertension agents, one of which is a…
- Trial name
- NCT00442286
- Testing
- Rheos® Baroreflex Hypertension System
- Where
- 44 sites in United States, Germany and 1 more
- Volunteers
- 591 people
- Sponsor
- CVRx, Inc.
Hypertension
Aliskiren Plus HCTZ Compared to Aliskiren in Metabolic Syndrome Patients With Stage 2 Systolic Hypertension
The purpose of the study is to evaluate the blood pressure lowering effect and safety of aliskiren in combination with Hydrochlorothiazide (HCTZ) compared to aliskiren monotherapy when given to metabolic syndrome patients with…
- Trial name
- AIMS (NCT00797316)
- Testing
- Aliskiren, Hydrochlorothiazide
- Where
- United States
- Volunteers
- 532 people
- Sponsor
- Novartis
Resistant Hypertension
A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant Hypertension
This is a Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety, tolerability and the effect of 2 mg Baxdrostat vs.
- Trial name
- Bax24 (NCT06168409)
- Testing
- Baxdrostat
- Where
- 102 sites in United States, Argentina and 20 more
- Volunteers
- 218 people
- Sponsor
- AstraZeneca
Renal Artery Stenosis, Hypertension, Renovascular
Renal Stent Placement for the Treatment of Renal Artery Stenosis in Patients With Resistant Hypertension
The purpose of this trial is to test how well the iCAST™ RX Stent works in patients diagnosed with atherosclerotic renal artery stenosis and whether or not increased blood flow by the stent will help to control blood pressure.
- Trial name
- ARTISAN (NCT01673373)
- Testing
- iCAST™ Rx Stent System
- Where
- 12 sites in United States
- Volunteers
- 68 people
- Sponsor
- Atrium Medical Corporation
Hypertension
A Study to Evaluate the Efficacy and Safety of LCI699 Compared to Placebo in Participants With Resistant Hypertension
This study assessed the blood pressure effect, safety and tolerability of LCI699 compared to placebo and eplerenone in participants with resistant hypertension.
- Trial name
- NCT00817635
- Testing
- LCI699, Eplerenone
- Where
- 38 sites in United States, Iceland
- Volunteers
- 155 people
- Sponsor
- Novartis
Uncontrolled Hypertension, Resistant Hypertension
A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension
This is a Phase III, multicentre, randomised, double-blinded, placebo-controlled, parallel group study to evaluate the safety, tolerability and effect of 1 or 2 mg baxdrostat versus placebo, administered once daily (QD) orally…
- Trial name
- BaxHTN (NCT06034743)
- Testing
- Baxdrostat
- Where
- 263 sites in United States, Argentina and 27 more
- Volunteers
- 796 people
- Sponsor
- AstraZeneca
Resistant Hypertension
A Study Of Different Doses Of TBC3711 In Patients With Uncontrolled High Blood Pressure Already Taking Medications For High Blood Pressure.
The study was to determine the safe and effective dose of TBC3711 in patients with uncontrolled high blood pressure while already taking blood pressure medications.
- Trial name
- NCT00272961
- Testing
- TBC3711
- Where
- 12 sites in United States
- Volunteers
- 60 people
- Sponsor
- Pfizer
Hyperkalemia, Resistant Hypertension
Spironolactone With Patiromer in the Treatment of Resistant Hypertension in Chronic Kidney Disease
The purpose of this study is to determine if patiromer treatment in chronic kidney disease (CKD) subjects receiving spironolactone for the treatment of resistant hypertension will result in more persistent use of spironolactone…
- Trial name
- AMBER (NCT03071263)
- Testing
- Patiromer, Spironolactone
- Where
- 40 sites in United States, Bulgaria and 7 more
- Volunteers
- 295 people
- Sponsor
- Relypsa, Inc.
High Blood Pressure, Metabolic Syndrome
Comparison of Aliskiren and Amlodipine on Insulin Resistance and Endothelial Dysfunction in Patients With Hypertension and Metabolic Syndrome
The purpose of this study was to determine the effects of Aliskiren on insulin resistance (IR) and endothelial dysfunction (ED) in patients with high blood pressure and metabolic syndrome.
- Conditions
- High Blood Pressure, Metabolic Syndrome, Insulin Resistance, Endothelial Dysfunction
- Trial name
- NCT00417170
- Testing
- Aliskiren, Amlodipine
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Novartis Pharmaceuticals